1 Ozympic is not FDA approved for weight loss. Providers may, at their clinical discretion, remove it from the label if deemed appropriate for their patient.
of the
2 With a low-calorie diet and increased physical activity. In a 71-week double-blind, placebo-controlled trial, 27.9% of overweight or obese participants receiving oral semaglutide 25 mg lost ≥20% of body weight at 64 weeks compared with 3.1% of the placebo group. The average weight loss in the treatment group was 13.6% of body weight, compared to 2.4% in the placebo group. All participants also received lifestyle recommendations.
of the
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by the use of forward-looking terms, including the words “anticipate,” “anticipate,” “intend,” “plans,” “decisions,” “may,” “will,” “soon,” “likely,” “potential,” “future,” “future,” “hope,” or “should,” or, in any case, or their negative terms, or in other contexts, a variant thereof. There can be no assurance that actual results will not differ materially from expectations. Such statements include, but are not limited to, statements regarding our new strategy for weight loss care therapies, including GLP-1s and plans to provide GLP-1 customers with access to a broader class of FDA-approved drugs; statements about the expected availability of branded new Nordisk products on our platform, including the expected availability of such products, the available dosages for such products, the expected price of such products, and/or the time of availability of such products; Statements regarding providers’ ability to offer comprehensive plans that combine FDA-approved GLP-1 medications with 24/7 care team access and educational support; and statements about expanded access to treatment options on our platform. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
of the
Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs about future developments and their potential impact on us. Future developments that affect us may not be what we expect. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that could cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the content (branded and blended) available on our platform, and timing and logistical considerations related to updating access to customer feedback; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options on our platform; changes in the application, interpretation, and enforcement of health care, consumer protection or privacy laws or regulations applicable to our business; the timing, outcome or effect of this announcement on ongoing litigation, governmental actions or regulatory pronouncements; and other factors described in the Risk Factors and Other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. In addition, at this time we cannot estimate or predict the impact any collaboration with Novo Nordisk and/or any changes in our GLP-1 business may have on our future results, including revenue or EBITDA.
of the
If one or more of these risks or uncertainties materialize, or any of our assumptions prove incorrect, actual results may differ materially from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of March 18, 2026. We do not assume any responsibility (and expressly disclaim any responsibility) to update or revise forward-looking statements, or to update reasons that actual results may differ from those anticipated in the future or as other information, if necessary, other than as further information in the future. Applicable warranty law. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and conditions that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those expressed or implied by the forward-looking statements in this communication.
#era #weight #management